Mesoblast Limited (NASDAQ:MESO) Short Interest Update

Mesoblast Limited (NASDAQ:MESO) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totalling 1,800,000 shares, a growth of 34.3% from the December 15th total of 1,340,000 shares. Based on an average trading volume of 384,900 shares, the short-interest ratio is currently 4.7 days.

Hedge Funds Weigh In On Mesoblast

A number of hedge funds have recently bought and sold shares of the company. Jane Street Group LLC raised its stake in Mesoblast by 46.4% during the third quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after buying an additional 26,959 shares in the last quarter. Marshall Wace LLP bought a new position in Mesoblast during the second quarter worth $562,000. Lazari Capital Management Inc. lifted its stake in Mesoblast by 6.6% during the second quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company’s stock worth $364,000 after purchasing an additional 3,300 shares during the last quarter. XY Capital Ltd acquired a new position in Mesoblast in the third quarter worth $244,000. Finally, Creative Planning bought a new stake in Mesoblast during the third quarter valued at $147,000. 1.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

MESO has been the subject of several recent research reports. Piper Sandler increased their price objective on shares of Mesoblast from $11.00 to $15.00 and gave the company an “overweight” rating in a research report on Thursday, December 19th. Jefferies Financial Group lowered shares of Mesoblast from a “buy” rating to a “hold” rating in a report on Monday, December 23rd. Finally, Maxim Group upgraded shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $13.50.

Mesoblast Stock Down 2.5 %

MESO traded down $0.43 during trading on Thursday, hitting $16.67. The company had a trading volume of 543,629 shares, compared to its average volume of 655,004. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. Mesoblast has a 1-year low of $1.61 and a 1-year high of $22.00. The business has a 50-day moving average of $13.76 and a 200-day moving average of $9.69.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.